WilmerHale Advises Akouos Inc. in its Initial Public Offering

WilmerHale Advises Akouos Inc. in its Initial Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On June 30, 2020, Akouos Inc., a Boston-based precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, announced the closing of its initial public offering of 14,375,000 shares of common stock at a public offering price of $17.00 per share, including 1,875,000 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for gross proceeds of $244.4 million, before underwriting discounts and commissions and offering expenses payable by Akouos. All shares were offered by Akouos.

The company’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “AKUS” on June 26, 2020.

The deal team representing Akouos was led by Rosemary Reilly and Molly Fox.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel